1289 COMPARISON OF CO-MORBIDITY AT BASELINE AND RENAL FUNCTION OUTCOME IN PATIENTS WITH NEPHRECTOMY FOR RENAL MASSES AND MATCHED LIVING RENAL DONORS

Introduction:Most of patients with chronic renal failure are affected by normochromic, normocytic anemia caused by different etiological factors. Anemia causes a series of symptoms in chronic renal failure, which can hardly be recognized from the uremic signs. Anemia adds to morbidity and mortality rates in patients affected by advanced chronic renal failure. Blood count partially improves during the first months after starting the chronic renal replacement therapy, in correlation with the quality of depuration program, with extension of erythrocyte lifetime and with hemoconcentration due to reduction of plasma volume. Recent trials found that higher residual renal function (RRF) significantly reduced co-morbidity, the rate and duration of hospitalization and risk of treatment failure. Objective: The aim of the study was to follow blood count parameters in 32 patients on chronic continuous ambulatory peritoneal dialysis (CAPD) during the first six months of treatment, to evaluate the influence of demographic and clinical factors on blood count and RRF, and to examine the correlation between RRF and blood count parameters. Method: A total of 32 patients affected by end-stage renal disease of different major cause during the first six months of CADP treatment were studied. RRF and blood count were evaluated as well as their relationship during the follow-up. Results: Blood count significantly improved in our patients during the first six months of CAPD treatment even if Hb and HTC failed to reach normal values. Iron serum level slightly decreased because of more abundant erythropoiesis and iron utilization during the first six months of treatment. RRF slightly decreased. After six months of CAPD treatment, the patients with higher RRF had significantly higher Hb, HTC and erythrocyte number and a lot of positive correlations between RRF and anemia markers were observed. Conclusion: After 6-month follow-up period, the patients with higher RRF had significantly higher blood count parameters, and several positive correlations between RRF and blood count markers were confirmed.

Download Full-text

Renal function after percutaneous cryoablation of renal masses

Radiologia Brasileira ◽

10.1590/0100-3984.2020.53.3e1 ◽

2020 ◽

Vol 53 (3) ◽

pp. V-VI

Author(s):

Sergio Ajzen

Keyword(s):

Renal Function ◽

Renal Masses ◽

Percutaneous Cryoablation

Download Full-text

Split renal function in patients with renal masses: utility of parenchymal volume analysis vs nuclear renal scans

BJU International ◽

10.1111/bju.14997 ◽

2020 ◽

Vol 125 (5) ◽

pp. 686-694 ◽

Cited By ~ 1

Author(s):

Yunlin Ye ◽

Hajime Tanaka ◽

Yanbo Wang ◽

Rebecca A. Campbell ◽

Diego Aguilar Palacios ◽

...

Keyword(s):

Renal Function ◽

Renal Masses ◽

Volume Analysis ◽

Split Renal Function

Download Full-text

Renal function and oncologic outcomes in nephron sparing surgery for renal masses in solitary kidneys

World Journal of Urology ◽

10.1007/s00345-010-0576-9 ◽

2010 ◽

Vol 29 (3) ◽

pp. 343-348 ◽

Cited By ~ 13

Author(s):

Daniel J. Lee ◽

Greg Hruby ◽

Mitchell C. Benson ◽

James M. McKiernan

Keyword(s):

Renal Function ◽

Nephron Sparing Surgery ◽

Oncologic Outcomes ◽

Renal Masses ◽

Nephron Sparing

Download Full-text

Prevalence of renal insufficiency in cancer patients: Data from the IRMA-2 study

Journal of Clinical Oncology ◽

10.1200/jco.2009.27.15_suppl.9559 ◽

2009 ◽

Vol 27 (15_suppl) ◽

pp. 9559-9559 ◽

Cited By ~ 3

Author(s):

N. Janus ◽

S. Oudard ◽

P. Beuzeboc ◽

J. Gligorov ◽

I. Ray-Coquard ◽

...

Keyword(s):

Renal Function ◽

Renal Insufficiency ◽

Cancer Patients ◽

Anticancer Drugs ◽

Dosage Adjustment ◽

Phase 1 ◽

Time Data ◽

Cross Sectional ◽

Co Morbidity ◽

High Prevalence

9559 Background: The IRMA-1 study reported the high prevalence of renal insufficiency (RI) in 4,684 cancer patients, with a glomerular filtration rate (GFR) <90 and <60 ml/min/1.73m2 for 52.9% and 12.0%, respectively. Furthermore, almost 80% of patients were receiving nephrotoxic drugs or drugs necessitating dosage adjustment. The IRMA-2 study was started one year later, in different patients, and consisted of 2 phases: 1) a cross-sectional study, similar to IRMA-1, and 2) a 2-year retrospective follow-up of the patients to describe the evolution of their renal function along with time. Data from the phase 1 were compared to the results of IRMA-1 in terms of RI prevalence. Methods: Data were collected for cancer patients presenting at one of the 19 IRMA-2 centers in March 2005: type of tumour, sex, age, weight, serum creatinine (SCR), and anticancer drugs. Dialysis, myeloma and lymphoma patients were not included. The prevalence of SCR>110 μmol/L was assessed. GFR was estimated with the aMDRD formula, anticancer drugs necessitating dosage adjustment and those potentially nephrotoxic were identified. Results: 4,945 patients (breast 1816, colorectal 747, lung 463, ovarian 294, prostate 251) were included in the IRMA-2 study. Median age 60.0, mean weight 66.2, 62.8% were women. The prevalence of an elevated SCR (SCR>110μmol/l) was 7.2% (vs. 7.2% in IRMA-1), that of a GFR < 90 ml/min/1.73m2 was 50.2% (vs. 52.9%) and that of a GFR < 60 ml/min/1.73m2 was 11.9% (vs. 12.0%) ( Table ). 73.2% of treated patients (n=3882) were receiving at least one drug needing dosage adjustment and 75.5% received at least one nephrotoxic drug (vs. 79.9 and 80.1%, respectively). Conclusions: The results of IRMA-2 and IRMA-1 confirm the high prevalence of RI in cancer patients, on 2 different cohorts of nearly 5,000 cancer patients each. This underlines that estimating renal function in cancer patients is mandatory and that this highly frequent co-morbidity should be considered. [Table: see text] No significant financial relationships to disclose.

Download Full-text

Does radiofrequency ablation preserve long-term renal function in patients with small renal masses?

Nature Clinical Practice Urology ◽

10.1038/ncpuro1156 ◽

2008 ◽

Vol 5 (8) ◽

pp. 420-421

Author(s):

Arieh L Shalhav ◽

Sergey A Shikanov

Keyword(s):

Renal Function ◽

Radiofrequency Ablation ◽

Small Renal Masses ◽

Renal Masses

Download Full-text

Laparoscopic Nephrectomy,Ex VivoPartial Nephrectomy, and Autotransplantation for the Treatment of Complex Renal Masses

Case Reports in Urology ◽

10.1155/2014/354104 ◽

2014 ◽

Vol 2014 ◽

pp. 1-4

Author(s):

Jasmir Gopal Nayak ◽

Joshua Koulack ◽

Thomas Brian McGregor

Keyword(s):

Renal Function ◽

Partial Nephrectomy ◽

Ex Vivo ◽

Laparoscopic Nephrectomy ◽

Cell Renal Cell Carcinoma ◽

Renal Masses ◽

Local Experience ◽

Nephron Sparing ◽

Stable Renal Function ◽

Clinical Dilemma

In the contemporary era of minimally invasive surgery, very few T1/T2 renal lesions are not amenable to nephron-sparing surgery. However, centrally located lesions continue to pose a clinical dilemma. We sought to describe our local experience with three cases of laparoscopic nephrectomy,ex vivopartial nephrectomy, and autotransplantation. Laparoscopic donor nephrectomy was performed followed by immediate renal cooling and perfusion with isotonic solution. Back-table partial nephrectomy, renorrhaphy, and autotransplantation were then performed. Mean warm ischemia (WIT) and cold ischemic times (CIT) were 2 and 39 minutes, respectively. Average blood loss was 267 mL. All patients preserved their renal function postoperatively. Final pathology confirmed pT1, clear cell renal cell carcinoma with negative margins in all. All are disease free at up to 39 months follow-up with stable renal function. In conclusion, the described approach remains a viable option for the treatment of complex renal masses preserving oncological control and renal function.

Download Full-text